Alembic Limited

Vadodara, India Founded: 1907 • Age: 119 yrs Listed
Active pharmaceutical ingredients are manufactured by Alembic.
Request Access
Report Incorrect Data
Page last updated

About Alembic Limited

Alembic Limited is a publicly listed company based in Vadodara (India) founded in 1907. Active pharmaceutical ingredients are manufactured by Alembic. The company has 323 employees. Its chief executive, as recorded, is Malika C Amin. Its website alembiclimited.com draws about 12 thousand monthly visits. Its Indian entity Alembic Limited reported revenue of ₹313 Cr. Its focus areas include Diversified Pharmaceuticals and Drugs.

Company details

Alembic was established in 1907 and is headquartered in Vadodara, India. Operations focus on the production of active pharmaceutical ingredients within the healthcare sector. The company maintains facilities for manufacturing these essential components used in drug formulations. Leadership is provided by Malika C Amin as CEO and Managing Director. Activities are centered in the pharmaceutical industry, supporting global supply chains from its Indian base.

  • Headquarters Vadodara, India
  • Employees 323
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website alembiclimited.com
  • Legal Name Alembic Limited
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹2,318 Cr

    ALEMBICLTD · NSE

  • Share Price
    ₹86.73

    -3.93% today

  • Revenue
    ₹240 Cr

    FY 2025-26 · +8.2% YoY

  • EBITDA
    ₹90.47 Cr

    Margin 37.7%

  • Net Profit
    ₹311 Cr

    FY 2025-26 · +0.7% YoY

  • P/E (TTM)
    7.4x

    P/B 1.0x

  • ROE
    5.3%

    ROCE 6.2%

  • Debt / Equity
    0.01

    Interest cover 2.9x

  • Employee Count
    323

Board of directors of Alembic Limited (Alembic Limited)

Alembic Limited is the primary company behind Alembic Limited. The boards of the 3 registered companies of Alembic Limited currently have 19 directors; the longest-serving is Chirayu Ramanbhai Amin, appointed in 1967. 38 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Chirayu Ramanbhai Amin
DIN 00242549
Director20 Aug 196759 yrs 2 moAlembic Limited, Alembic Pharmaceuticals Limited
Malika Chirayu Amin
DIN 00242613
Director02 Jul 198838 yrs 3 moAlembic Limited
Rajkumar Shreeram Baheti
DIN 00332079
Whole-time director16 Jun 201016 yrs 4 moAlembic Pharmaceuticals Limited
Pranav Chirayu Amin
DIN 00245099
Managing Director31 Mar 201115 yrs 6 moAlembic Pharmaceuticals Limited
Shaunak Chirayu Amin
DIN 00245523
Managing Director02 May 201313 yrs 5 moAlembic Pharmaceuticals Limited
Samir Harendra Patel
DIN 06571207
Director07 Jul 201412 yrs 3 moAlembic City Limited
Udit Chirayu Amin
DIN 00244235
Managing Director28 Mar 201610 yrs 6 moAlembic Limited
Rati Desai
DIN 08535681
Director13 Aug 20197 yrs 2 moAlembic Limited, Alembic City Limited
Rasesh Jayant Shah
DIN 00113641
Director26 Aug 20197 yrs 1 moAlembic City Limited
Ashok Kumar Barat
DIN 00492930
Director10 Feb 20224 yrs 8 moAlembic Pharmaceuticals Limited
Jai Shishir Diwanji
DIN 00910410
Director05 May 20233 yrs 5 moAlembic Pharmaceuticals Limited
Girish Srinivasiah Hirode
DIN 10145777
Director10 Aug 20233 yrs 2 moAlembic Limited
Manish Santoshkumar Kejriwal
DIN 00040055
Director31 Mar 20242 yrs 6 moAlembic Pharmaceuticals Limited
Nilesh Bhikhabhai Mistry
DIN 06571209
Director09 May 20242 yrs 5 moAlembic City Limited
Geeta Amit Goradia
DIN 00074343
Director03 Feb 20251 yr 8 moAlembic Pharmaceuticals Limited
Sanjeev Virendra Shah
DIN 00106702
Director07 Feb 20251 yr 8 moAlembic Limited
Mayurdhvaj Dilipsinh Jadeja
DIN 00799518
Director07 Feb 20251 yr 8 moAlembic Limited
Jain Parkash
DIN 10922687
Director08 Feb 20251 yr 8 moAlembic Limited
Sujit Jaysukh Bhayani
DIN 01767427
Additional Director18 Jun 20264 moAlembic Pharmaceuticals Limited

People of Alembic Limited

3 people are tracked at Alembic Limited (2 in leadership, 1 in team); the tracked headcount is 323.

NameRoleGroup
Malika C Amin
CEO & Managing DirectorLeadership
Malika Chirayu Amin
Chief Executive OfficerLeadership
Rasesh Shah
Name Of Nodal OfficerTeam
Premium access

Complete people profiles for Alembic Limited

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Alembic Limited

Alembic Limited is a publicly listed company on the NSE with ticker symbol ALEMBICLTD in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date22 Sep 1999
  • Listed onNSE: ALEMBICLTD
  • Listed entityAlembic Limited
  • Exchange sectorHealth technology
  • ISININE426A01027
  • Share price₹98.68 (+0.42% on the day) · 2026-10-14
  • Market capitalisation₹2,523 Cr
  • Price to earnings7.9
  • EPS (diluted, trailing year)₹12.49
  • Dividend yield2.44%
  • Volume (last session)297,507

Financials of Alembic Limited

Exchange-reported figures of Alembic Limited, the listed company behind Alembic Limited (NSE: ALEMBICLTD).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹240 Cr
+8.2% YoY
EBITDA
₹90.47 Cr
-3.5% YoY
Profit After Tax
₹311 Cr
+0.7% YoY
Net Worth
₹2,445 Cr
+4.6% YoY
Total Assets
₹2,473 Cr
+4.4% YoY
Total Debt
₹10.64 Cr
-26.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue24022215712778.2273.5273.93
Revenue growth+8.2%+40.9%+23.8%+62.7%+6.4%-0.6%-
EBITDA90.4793.7256.8629.7213.9211.063.28
EBITDA margin+37.7%+42.2%+36.1%+23.4%+17.8%+15.0%+4.4%
Profit before tax14915610386.7997.8517.0393.16
Net profit311309268198219339328
Net profit margin+129.8%+139.4%+170.0%+155.9%+279.9%+461.2%+443.2%
EPS (₹)12.3612.1010.467.428.6513.3512.82
Balance sheet
Total assets2,4732,3682,2082,0862,5042,3031,423
Net worth2,4452,3392,1862,0782,4972,2971,418
Total debt10.6414.459.150.000.000.280.00
Cash & bank3.294.372.471.901.856.5758.86
Net working capital3.3543.0837.4942.9249.7126.3663.32
Cash flow
Cash from operations12086.3722.6938.85(17.75)(2.18)6.54
Cash from investing(53.86)(26.58)25.847.3018.85(34.87)56.72
Cash from financing(67.50)(58.34)(48.19)(46.39)(5.82)(15.36)(6.41)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue48.7460.0474.3455.8649.7560.2757.9252.91
Revenue growth (YoY)-2.0%-0.4%+28.4%+5.6%-2.0%---
Other income5.962.142.3164.923.592.964.3765.60
EBITDA15.4620.2127.4423.2419.5927.3326.4019.58
EBITDA margin+31.7%+33.7%+36.9%+41.6%+39.4%+45.3%+45.6%+37.0%
Depreciation3.483.343.442.822.792.752.692.68
Interest0.600.570.550.560.590.620.690.67
Profit before tax17.3418.4425.7684.7819.8026.9227.3981.83
Tax1.648.833.298.722.003.171.304.52
Net profit15.709.6122.4776.0617.8023.7526.0977.31
EPS (₹)2.532.612.345.002.402.672.554.71
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue23221415212375.9772.3073.69
Revenue growth+8.2%+40.8%+23.6%+62.1%+5.1%-1.9%-
EBITDA87.7089.5656.2427.4012.9010.733.73
EBITDA margin+37.8%+41.8%+36.9%+22.3%+17.0%+14.8%+5.1%
Profit before tax14715210384.9997.2616.5293.69
Net profit11914192.0987.0382.599.6292.08
Net profit margin+51.3%+65.6%+60.5%+70.7%+108.7%+13.3%+125.0%
EPS (₹)4.855.533.623.093.340.523.64
Balance sheet
Total assets8468778268321,017832487
Net worth8218538098291,014827483
Total debt10.6414.459.150.000.000.280.00
Cash & bank2.974.192.191.791.596.4657.86
Net working capital5.5242.2535.2444.5049.7425.8263.57
Cash flow
Cash from operations11781.0325.3334.70(21.87)(1.12)5.48
Cash from investing(52.04)(21.79)22.6011.2922.66(35.15)56.79
Cash from financing(66.79)(57.70)(47.77)(46.08)(5.66)(15.27)(6.40)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue46.2757.7372.2854.0447.8958.2255.9751.10
Revenue growth (YoY)-3.4%-0.8%+29.1%+5.8%-2.4%---
Other income5.552.412.1064.803.462.784.2565.59
Total expenses32.2338.1845.2331.5229.3132.2130.2632.72
EBITDA14.0419.5527.0522.5218.5826.0125.7118.38
EBITDA margin+30.3%+33.9%+37.4%+41.7%+38.8%+44.7%+45.9%+36.0%
Depreciation3.383.253.342.722.702.662.592.59
Interest0.370.370.370.400.420.450.520.51
Profit before tax15.8418.3425.4484.2018.9225.6826.8580.87
Tax1.168.813.188.571.802.851.164.27

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue48.7460.0474.3455.8649.7560.2757.9252.91
Revenue growth (YoY)-2.0%-0.4%+28.4%+5.6%-2.0%---
Other income5.962.142.3164.923.592.964.3765.60
EBITDA15.4620.2127.4423.2419.5927.3326.4019.58
EBITDA margin+31.7%+33.7%+36.9%+41.6%+39.4%+45.3%+45.6%+37.0%
Depreciation3.483.343.442.822.792.752.692.68
Interest0.600.570.550.560.590.620.690.67
Profit before tax17.3418.4425.7684.7819.8026.9227.3981.83
Tax1.648.833.298.722.003.171.304.52
Net profit15.709.6122.4776.0617.8023.7526.0977.31
EPS (₹)2.532.612.345.002.402.672.554.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue24022215712778.2273.5273.93
Revenue growth+8.2%+40.9%+23.8%+62.7%+6.4%-0.6%-
Other income72.9774.8954.7764.2689.1810.2793.40
Total expenses15012810197.5264.3062.4670.65
Employee cost37.4427.3123.0324.0421.4722.6020.79
EBITDA90.4793.7256.8629.7213.9211.063.28
EBITDA margin+37.7%+42.2%+36.1%+23.4%+17.8%+15.0%+4.4%
Depreciation12.3910.637.846.724.863.943.23
Interest2.282.471.110.470.390.360.29
Profit before tax14915610386.7997.8517.0393.16
Tax22.8310.939.826.1811.663.200.13
Net profit311309268198219339328
Net profit margin+129.8%+139.4%+170.0%+155.9%+279.9%+461.2%+443.2%
EPS (₹)12.3612.1010.467.428.6513.3512.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital51.3651.3651.3651.3651.3651.3651.36
Reserves & surplus2,3942,2872,1342,0272,4452,2461,367
Shareholders' funds (net worth)2,4452,3392,1862,0782,4972,2971,418
Minority interest0.000.000.000.000.000.000.00
Secured loans10.6414.459.150.000.000.280.00
Unsecured loans0.000.000.000.000.000.000.00
Total debt10.6414.459.150.000.000.280.00
Total liabilities2,4732,3682,2082,0862,5042,3031,423
Assets
Gross block535460410355324288244
Net block472409369321297265225
Capital work in progress1.500.001.100.130.195.843.08
Investments1,9741,9001,7861,7542,2082,0471,133
Inventories52.2499.3992.6088.6186.8754.2835.41
Sundry debtors31.9029.9719.7623.4515.2213.818.98
Cash & bank balances3.294.372.471.901.856.5758.86
Loans & advances13.1916.0411.2212.7713.5410.845.86
Total current assets10115012612711785.50109
Total current liabilities97.2710788.5683.8167.7759.1445.79
Net working capital3.3543.0837.4942.9249.7126.3663.32
Total assets2,4732,3682,2082,0862,5042,3031,423
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2.711.260.931.175.8958.302.01
Net cash from operating activities12086.3722.6938.85(17.75)(2.18)6.54
Net cash from investing activities(53.86)(26.58)25.847.3018.85(34.87)56.72
Net cash from financing activities(67.50)(58.34)(48.19)(46.39)(5.82)(15.36)(6.41)
Net change in cash(1.30)1.450.33(0.24)(4.72)(52.41)56.85
Closing cash3.294.372.471.901.856.5758.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.2%+40.9%+23.8%+62.7%+6.4%-0.6%-
EBITDA growth-3.5%+64.8%+91.3%+113.5%+25.9%+237.2%-
PBT growth-4.3%+51.5%+18.3%-11.3%+474.6%-81.7%+108.6%
Net income growth+0.7%+15.5%+35.0%-9.4%-35.4%+3.5%-
Revenue CAGR (3Y)+23.6%+41.6%+28.9%+19.8%-14.2%-16.3%-20.5%
EBITDA CAGR (3Y)+44.9%+88.8%+72.6%+108.5%-8.3%-0.2%+53.3%
Profitability & leverage
Net income margin+52.5%+65.2%+59.0%+63.4%+110.2%+18.8%+125.8%
Return on capital employed+6.2%+6.9%+4.8%+3.8%+4.1%+0.7%+7.1%
Return on net worth+5.3%+6.4%+4.4%+3.5%+3.6%+0.5%+7.1%
Debt / equity0.010.010.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover2.922.972.262.044.305.06580.00
Efficiency & per share
Fixed asset turnover0.480.510.410.370.260.280.32
Inventory turnover3.172.311.741.451.111.642.09
Debtors turnover7.768.927.296.585.396.456.57
EPS (₹)12.3612.1010.467.428.6513.3512.82
Dividend per share (₹)2.402.402.402.201.800.200.60
Book value per share (₹)95.2291.0785.1180.9397.2389.4555.22
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue46.2757.7372.2854.0447.8958.2255.9751.10
Revenue growth (YoY)-3.4%-0.8%+29.1%+5.8%-2.4%---
Other income5.552.412.1064.803.462.784.2565.59
Total expenses32.2338.1845.2331.5229.3132.2130.2632.72
EBITDA14.0419.5527.0522.5218.5826.0125.7118.38
EBITDA margin+30.3%+33.9%+37.4%+41.7%+38.8%+44.7%+45.9%+36.0%
Depreciation3.383.253.342.722.702.662.592.59
Interest0.370.370.370.400.420.450.520.51
Profit before tax15.8418.3425.4484.2018.9225.6826.8580.87
Tax1.168.813.188.571.802.851.164.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue23221415212375.9772.3073.69
Revenue growth+8.2%+40.8%+23.6%+62.1%+5.1%-1.9%-
Other income72.7774.5154.6264.1189.099.9793.47
Total expenses14412596.0195.7663.0761.5769.96
Employee cost37.4427.3123.0324.0421.4722.6020.79
EBITDA87.7089.5656.2427.4012.9010.733.73
EBITDA margin+37.8%+41.8%+36.9%+22.3%+17.0%+14.8%+5.1%
Depreciation12.0110.247.466.364.503.913.23
Interest1.571.830.690.160.230.270.28
Profit before tax14715210384.9997.2616.5293.69
Tax22.3510.059.835.7311.573.150.13
Net profit11914192.0987.0382.599.6292.08
Net profit margin+51.3%+65.6%+60.5%+70.7%+108.7%+13.3%+125.0%
EPS (₹)4.855.533.623.093.340.523.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital51.3651.3651.3651.3651.3651.3651.36
Reserves & surplus770802757778962775432
Shareholders' funds (net worth)8218538098291,014827483
Secured loans10.6414.459.150.000.000.280.00
Unsecured loans0.000.000.000.000.000.000.00
Total debt10.6414.459.150.000.000.280.00
Total liabilities8468778268321,017832487
Assets
Gross block531456406351321284244
Net block470406366318294261225
Capital work in progress1.500.001.100.130.195.843.08
Investments349414411503726581197
Inventories52.2499.3992.6088.6186.8754.2835.41
Sundry debtors30.2127.8917.4022.6814.9013.108.89
Cash & bank balances2.974.192.191.791.596.4657.86
Loans & advances12.3715.2810.4712.4613.2710.096.71
Total current assets97.7914712312611783.93109
Total current liabilities92.2710487.4281.0466.8958.1145.30
Net working capital5.5242.2535.2444.5049.7425.8263.57
Total assets8468778268321,017832487
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2.530.990.830.925.7857.301.99
Net cash from operating activities11781.0325.3334.70(21.87)(1.12)5.48
Net cash from investing activities(52.04)(21.79)22.6011.2922.66(35.15)56.79
Net cash from financing activities(66.79)(57.70)(47.77)(46.08)(5.66)(15.27)(6.40)
Net change in cash(1.43)1.540.16(0.09)(4.86)(51.53)55.87
Closing cash2.974.192.191.791.596.4657.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.2%+40.8%+23.6%+62.1%+5.1%-1.9%-
EBITDA growth-2.1%+59.3%+105.3%+112.4%+20.2%+187.7%-
PBT growth-3.4%+48.0%+20.9%-12.6%+488.7%-82.4%+109.6%
Net income growth-15.5%+52.8%+5.8%+5.4%+758.5%-89.6%-
Revenue CAGR (3Y)+23.5%+41.3%+28.2%+18.7%-15.0%-16.8%-20.6%
EBITDA CAGR (3Y)+47.4%+90.8%+73.7%+94.4%-10.7%-1.2%+60.0%
Profitability & leverage
Net income margin+53.7%+66.2%+61.0%+64.4%+112.8%+18.5%+127.0%
Return on capital employed+17.2%+18.1%+12.5%+9.2%+10.6%+1.8%+20.8%
Return on net worth+14.9%+17.1%+11.3%+8.6%+9.3%+1.5%+20.9%
Debt / equity0.010.010.010.000.000.000.00
Long-term debt / equity0.010.010.000.000.000.000.00
Interest cover2.072.311.410.762.743.9656.00
Efficiency & per share
Fixed asset turnover0.470.500.400.370.250.270.31
Inventory turnover3.062.231.681.401.081.612.08
Debtors turnover7.989.477.606.555.436.586.58
EPS (₹)4.855.533.623.093.340.523.64
Dividend per share (₹)2.402.402.402.201.800.200.60
Book value per share (₹)31.9933.2331.5032.2839.4832.2018.81

Web traffic of Alembic Limited

The website of Alembic Limited (alembiclimited.com) receives about 12.1K visits a month.

  • Monthly visits
    12.1K

    ▲ 82.5% vs previous month

Similar websites

Websites whose visitors overlap most with Alembic Limited. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
India Infoline
indiainfoline.com
100%
630.1K#78,261View details
alembic.co.in
alembic.co.in
98%
#514,293–
moneycontrol.com
moneycontrol.com
80%
#489–
EMIS
securities.com
60%
View details
in.reuters.com
in.reuters.com
60%
–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 11 similar websites and full traffic analytics for Alembic Limited

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 11 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Alembic Limited

Hyundai Motor India to trade ex-dividend on August 5 among 21 others. Do you own? - The Economic Times
Economic Times • 1 year ago
Sensex climbs 1,000 pts, mid & smallcap stocks surge, Reliance, RBL Bank, Shriram Finance, Tata Tech, IndusInd, UltraTech shares in action
Thehindubusinessline • 1 year ago
Watch these stocks: M&M, SML Isuzu, TVS Motor, TVS Holdings, IREDA, Reliance Industries, NTPC Green Energy, Aurobindo Pharma, Zydus Life, Alembic, Biocon, PTC India, JSW Steel, GAIL India, Concord
Thehindubusinessline • 1 year ago
Stock Market Live Updates 3 April 2025: Indian markets flat as Trump’s 26% tariff hits exports; global equities slide
Thehindubusinessline • 1 year ago
Trump Tariffs Announcement Live: Trump unleashes sweeping tariffs, fuelling US manufacturing push and global trade worries
Thehindubusinessline • 1 year ago
Alembic Pharma signs deal with Amlan International to bring poultry health solutions to India
Thehindubusinessline • 1 year ago
Stock Market Highlights 10 February 2025: Sensex settles at 77,311.80; Nifty drops 178.35 points to 23,381.60
Thehindubusinessline • 1 year ago
Stock Market Live Updates 10 February 2025: Sensex, Nifty open in the red
Thehindubusinessline • 1 year ago
Alembic Pharma secures FDA approval for Schizophrenia treatment, stocks in red
Thehindubusinessline • 2 years ago
Trade Spotlight: How should you trade Alembic, Huhtamaki, Delhivery, Voltas, Aarti Industries, and others on Tuesday?
Moneycontrol • 2 years ago
Premium access

Complete news archive for Alembic Limited

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Alembic Limited on our blog

Frequently Asked Questions about Alembic Limited

Alembic Limited was founded in 1907.

Alembic Limited is headquartered in Vadodara, India. It is registered at Vadodara, Gujarat, India.

Malika C Amin is the CEO of Alembic Limited, as recorded in our data.

Alembic Limited has 323 employees.

The primary company behind Alembic Limited, Alembic Limited, reported revenue of ₹313 Cr for FY 2026, up 8% year on year.

Alembic was established in 1907 and is headquartered in Vadodara, India. Operations focus on the production of active pharmaceutical ingredients within the healthcare sector. The company maintains facilities for manufacturing these essential components used in drug formulations. Leadership is provided by Malika C Amin as CEO and Managing Director. Activities are centered in the pharmaceutical industry, supporting global supply chains from its Indian base.

Yes, Alembic Limited is publicly traded on NSE under the ticker symbol ALEMBICLTD.

Alembic Limited is associated with 4 legal entities: Alembic Limited, Alembic Pharmaceuticals Limited, Shreno Ltd and others.

The legal entities of Alembic Limited currently have 23 directors, including Rati Desai, Chirayu Ramanbhai Amin, Malika Chirayu Amin and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available